Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-stage cell therapy company, announced that CEO Scott Requadt will present virtually at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-stage cell therapy company, announced that CEO Scott Requadt will present virtually at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The pre-recorded presentation will be available on May 24th at 7:00 AM ET on the Talaris website, where it will remain accessible for 90 days. Talaris is focused on developing transformative therapies for solid organ transplantation and severe immune and blood disorders, with corporate offices in Boston, a cell processing facility in Louisville, and research operations in Houston.
Details
News Market Reaction – TALS
The recorded move for TALS in the trading session of this news was -14.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
A webcast of the pre-recorded on-demand presentation will be made available Tuesday, May 24th starting at 7:00 AM ET, and can be accessed by visiting the investors section of the Talaris website at www.talaristx.com. The event will remain archived on the Talaris website for 90 days.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.